Literature DB >> 10678274

Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.

S Benson1, J Wu, S Padmanabhan, T W Kurtz, H A Pershadsingh.   

Abstract

This study was conducted to determine whether cultured human coronary artery and aorta vascular smooth muscle (VSM) cells express the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPARgamma); whether the thiazolidinedione troglitazone, a ligand for PPARgamma, would inhibit c-fos expression by these cells; and whether troglitazone would inhibit proliferation and migration induced in these cells by mitogenic growth factors. Using immunoblotting and reverse-transcriptase polymerase chain reaction (RT-PCR) techniques, we show that both human aorta and coronary artery VSM cell lines expressed PPARgamma protein and mRNA for both PPARgamma isoforms, PPARgamma1 and PPARgamma2. Immunocytochemical staining localized the PPARgamma protein primarily within the nucleus. Troglitazone inhibited basic fibroblast growth factor and platelet-derived growth factor-BB induced DNA synthesis in a dose-dependent manner and downregulated the growth-factor-induced expression of c-fos. Troglitazone also inhibited the migration of coronary artery VSM cells along a platelet-derived growth factor-BB concentration gradient. These findings demonstrate for the first time the expression and nuclear localization of PPARgamma in human coronary artery and aorta VSM cells. The data also suggest that the downregulation of c-fos expression, growth-factor-induced proliferation, and migration by VSM may, in part, be mediated by activation of the PPARgamma receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678274     DOI: 10.1016/s0895-7061(99)00148-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

1.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.

Authors:  Toru Akune; Shinsuke Ohba; Satoru Kamekura; Masayuki Yamaguchi; Ung-Il Chung; Naoto Kubota; Yasuo Terauchi; Yoshifumi Harada; Yoshiaki Azuma; Kozo Nakamura; Takashi Kadowaki; Hiroshi Kawaguchi
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 2.  Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.

Authors:  J Plutzky
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

3.  Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Authors:  Peter Zahradka; Natalia Yurkova; Brenda Litchie; Michael C Moon; Dario F Del Rizzo; Carla G Taylor
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

Review 4.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

Review 5.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

6.  The possible role of peroxisome proliferator-activated receptor gamma in heart failure.

Authors:  Natsuhiko Ehara; Koh Ono; Tatsuya Morimoto; Teruhisa Kawamura; Mitsuru Abe; Koji Hasegawa
Journal:  Exp Clin Cardiol       Date:  2004

7.  PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms.

Authors:  Jane E Ward; Haslinda Gould; Trudi Harris; John V Bonacci; Alastair G Stewart
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

8.  Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

Authors:  Islam Osman; Lakshman Segar
Journal:  Biochem Pharmacol       Date:  2015-11-28       Impact factor: 5.858

Review 9.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

10.  Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

Authors:  Hiroshi Hasegawa; Hiroyuki Takano; Issei Komuro
Journal:  PPAR Res       Date:  2010-08-12       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.